FDA accepts application for Lilly-BoehringerJardiance for adults with chronic kidney disease

 The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial, which showed Jardiance® (empagliflozin) tablets significantly reduced the risk of kidney disease progression* or cardiovascular death in adults with CKD by 28% (absolute risk reduction [ARR]: 3.8%) compared with placebo, both on top of standard of care.

https://www.biospace.com/article/releases/us-fda-accepts-supplemental-new-drug-application-for-jardiance-for-adults-with-chronic-kidney-disease/